EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio

Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support the Phase 1/2 clinical development of lead program SB-007 in Stargardt disease, a genetic eye disorder that causes progressive vision loss and blindnessFunding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other therapeutic areasView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-co-leads-usd-135-million-series-b-financing-in-splicebio-302478828.html

en | boerse | 67928714 |